Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
169.1 INR | -1.80% | +0.74% | +5.13% |
04-18 | Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA | MT |
02-14 | Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024 |
Sales 2024 * | 21.58B 259M 353M | Sales 2025 * | 26.33B 316M 431M | Capitalization | 76.65B 919M 1.26B |
---|---|---|---|---|---|
Net income 2024 * | 3.34B 39.97M 54.62M | Net income 2025 * | 4.07B 48.74M 66.59M | EV / Sales 2024 * | 3.55 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.91 x |
P/E ratio 2024 * |
23
x | P/E ratio 2025 * |
18.9
x | Employees | 852 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.99% |
Latest transcript on Marksans Pharma Limited
1 day | -1.80% | ||
1 week | +0.74% | ||
Current month | +11.58% | ||
1 month | +11.58% | ||
3 months | +17.59% | ||
6 months | +63.70% | ||
Current year | +5.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 92-04-15 | |
Director of Finance/CFO | 54 | 02-09-05 | |
Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sunny Sharma
BRD | Director/Board Member | 49 | 21-08-10 |
Chief Executive Officer | 52 | 92-04-15 | |
Director/Board Member | 52 | 14-09-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 169.1 | -1.80% | 129,127 |
24-04-26 | 172.2 | +3.18% | 182,447 |
24-04-25 | 166.9 | -0.57% | 92,766 |
24-04-24 | 167.8 | -0.94% | 98,746 |
24-04-23 | 169.4 | +0.95% | 144,938 |
Delayed Quote Bombay S.E., April 29, 2024 at 06:00 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- MARKSANS Stock
- MARKSANS Stock